(MENAFN- GetNews)
"Malignant Pleural Mesothelioma Pipeline Assessment 2024"According to DelveInsight's assessment, approximately 20+ key Pharmaceutical and biotechnology companies are working on over 20 pipeline drugs in the Malignant Pleural Mesothelioma therapeutics landscape. These therapies vary in their routes of administration (RoA), mechanisms of action (MoA), and molecular types. Several of these treatments are in advanced stages of clinical development and are expected to be launched in the coming years.
DelveInsight anticipates that the Malignant Pleural Mesothelioma market will undergo significant growth in the coming years, driven by increased healthcare spending worldwide and the introduction of emerging therapies. Ongoing research and development in the therapeutics segment are also expected to transform treatment dynamics and the market outlook.
Currently, major pharmaceutical and biotechnology companies such as AstraZeneca, Targovax, PharmaMar, Polaris Pharmaceuticals, and others are actively involved in drug development activities for Malignant Pleural Mesothelioma.
DelveInsight's,“Malignant Pleural Mesothelioma (MPM) - Pipeline Insight, 2024 ,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant Pleural Mesothelioma (MPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Malignant Pleural Mesothelioma Overview
Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the pleural surface. It is linked to previous asbestos exposure, with a latency period of approximately 40 years between fiber exposure and the onset of the disease. The global incidence of MPM has been rising steadily over the past decade and is expected to continue, reaching an estimated peak in 2020. The prognosis for MPM is poor, with a median survival ranging from 8 to 14 months from the time of diagnosis. Women generally have a more favorable outlook than men, but due to the occupational nature of the disease, there is a male predominance of 4:1. There are four main histological subtypes: epithelioid, sarcomatoid, biphasic or mixed, and desmoplastic. The majority of MPM cases are caused by prior exposure to asbestos, often occurring more than 40 years previously. Other causes of MPM include erionite (a mineral found in the rocks of Turkey), chest wall radiation, and simian virus.
Malignant Pleural Mesothelioma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Malignant Pleural Mesothelioma and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Malignant Pleural Mesothelioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Malignant Pleural Mesothelioma (MPM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
Interleukin-2 replacement
Peroxidase inhibitors
Immunologic cytotoxicity
CBLB protein expression inhibitor
Gene transference
Immunologic cytotoxicity
TRAIL receptor 2 agonist
Programmed cell death-1 receptor antagonist
Antibody-dependent cell cytotoxicity
Learn How the Ongoing Clinical & Commercial Activities will Affect the Malignant Pleural Mesothelioma Therapeutic Segment @
Malignant Pleural Mesothelioma Therapeutics Landscape
Several major pharmaceutical and biotechnology companies are developing therapies for Malignant Pleural Mesothelioma. Currently, MolMed is at the forefront of the therapeutics market with its Malignant Pleural Mesothelioma drug candidates in the most advanced stages of clinical development.
Leading Companies in the Malignant Pleural Mesothelioma Therapeutics Market Include:
ACADIA Pharmaceuticals, Aduro Biotech, Inc, AGC Biologics S.p.A, AstraZeneca, Atara Biotherapeutics, Bristol-Myers Squibb, Hoffmann-La Roche, Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceuticals, Lurbinectedin: PharmaMar, Merck Sharp & Dohme Corp., Amphera BV,
MolMed, Momotaro-Gene, Novartis, Novotech (Australia) Pty Limited, PharmaMar, Polaris Pharmaceuticals, RS Oncology, Sanofi, Sellas Life Sciences Group, Targovax, TCR2 Therapeutics, Ys Therapeutics, and many others.
Malignant Pleural Mesothelioma Emerging and Marketed Drugs Covered in the Report Include:
ATA2271: Atara Biotherapeutics
Galinpepimut-S (Vaccine): Sellas Life Sciences Group
IMFINZI: AstraZeneca
Lurbinectedin: PharmaMar
MesoPher: Amphera BV
MTG201 + nivolumab: Momotaro-Gene
NGR-TNF: MolMed
ONCOS-102: Targovax
Pegargiminase: Polaris Pharmaceuticals
Pembrolizumab: Merck & Co
RSO-021: RS Oncology
SAR-444245: Sanofi
TC-210: TCR2 Therapeutics
TECENTRIQ Plus AVASTIN: Hoffmann-La Roche
YS110: Ys Therapeutics
ZEPZELCA (lurbinectedin): PharmaMar
NovoTTF-100L System in Combination with Chemotherapy: NovoCure
OPDIVO (nivolumab): Bristol Myers Squibb/Ono Pharmaceutical
Ipilimumab + nivolumab: Bristol Myers Squibb
KEYTRUDA: Merck Sharp & Dohme
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Contents
1. Report Introduction
2. Executive Summary
3. Malignant Pleural Mesothelioma Current Treatment Patterns
4. Malignant Pleural Mesothelioma – DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Malignant Pleural Mesothelioma Late Stage Products (Phase-III)
7. Malignant Pleural Mesothelioma Mid-Stage Products (Phase-II)
8. Malignant Pleural Mesothelioma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Malignant Pleural Mesothelioma Discontinued Products
13. Malignant Pleural Mesothelioma Product Profiles
14. Key Companies in the Malignant Pleural Mesothelioma Market
15. Key Products in the Malignant Pleural Mesothelioma Therapeutics Segment
16. Dormant and Discontinued Products
17. Malignant Pleural Mesothelioma Unmet Needs
18. Malignant Pleural Mesothelioma Future Perspectives
19. Malignant Pleural Mesothelioma Analyst Review
20. Appendix
21. Report Methodology
Download Sample PDF to Explore the Key Offerings of the Report @
MENAFN29082024003238003268ID1108615050